Rivaroxaban para el tratamiento de la trombocitopenia inducida por heparina. Caso clínico

• Autores: Gustavo Rivera O., Óscar Corsi S., Andrés Pavlovic J., Andrés Aizman S., Pablo Varas A.
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 145, Nº. 9, 2017, págs. 1213-1217
• Idioma: español
• Títulos paralelos:
  • Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report
• Enlaces
  • Texto completo
• Resumen

  • Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.